[Which immunoglobulin heavy chains for which immunostimulatory antibodies?]

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Immunostimulatory antibodies are a key modality in cancer immunotherapy.
• Their efficacy depends on diverse mechanisms, including immune checkpoint blockade and T-cell modulation.
• The Fc and hinge regions of antibodies play a critical role in mediating these effects.

Purpose of the Study:

• To review the clinical experience with immunostimulatory antibodies in cancer.
• To highlight the importance of heavy chain isotype selection and engineering.
• To understand how antibody structure influences therapeutic mechanisms and outcomes.

Main Methods:

• Literature review focusing on clinical data and mechanistic studies.
• Analysis of antibody engineering strategies and their impact on Fc-mediated functions.
• Correlation of heavy chain properties with clinical efficacy and safety profiles.

Main Results:

• Different immunostimulatory antibody mechanisms (e.g., checkpoint blockade, T-cell depletion, receptor agonism) are influenced by antibody structure.
• Fc and hinge regions are critical for mediating effector functions and therapeutic responses.
• Clinical experience underscores the necessity of tailored antibody design for optimal anti-tumour activity.

Conclusions:

• The choice of heavy chain isotype and engineering is paramount for maximizing the therapeutic potential of immunostimulatory antibodies.
• Understanding Fc and hinge region contributions is essential for rational antibody design in cancer immunotherapy.
• Clinical insights provide valuable guidance for developing next-generation immunostimulatory antibodies.